Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Shenzhen Salubris Pharmaceuticals fair value estimate is CN¥38.01
- Current share price of CN¥31.73 suggests Shenzhen Salubris Pharmaceuticals is potentially trading close to its fair value
- Our fair value estimate is 1.4% higher than Shenzhen Salubris Pharmaceuticals' analyst price target of CN¥37.50
How far off is Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
The Method
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥663.5m | CN¥760.7m | CN¥1.34b | CN¥1.56b | CN¥1.73b | CN¥1.87b | CN¥1.99b | CN¥2.10b | CN¥2.20b | CN¥2.29b |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Analyst x1 | Analyst x1 | Est @ 10.54% | Est @ 8.23% | Est @ 6.62% | Est @ 5.49% | Est @ 4.70% | Est @ 4.14% |
Present Value (CN¥, Millions) Discounted @ 6.8% | CN¥621 | CN¥666 | CN¥1.1k | CN¥1.2k | CN¥1.2k | CN¥1.3k | CN¥1.3k | CN¥1.2k | CN¥1.2k | CN¥1.2k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥11b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.8%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥2.3b× (1 + 2.9%) ÷ (6.8%– 2.9%) = CN¥59b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥59b÷ ( 1 + 6.8%)10= CN¥31b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is CN¥41b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of CN¥31.7, the company appears about fair value at a 17% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240910/0-f316b073e0eacef26ea07ad97a0809be-0-153459762482fcc3ea9a94187e919987.png/big)
The Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Shenzhen Salubris Pharmaceuticals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Shenzhen Salubris Pharmaceuticals
- Debt is not viewed as a risk.
- Balance sheet summary for 002294.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Pharmaceuticals market.
- Annual revenue is forecast to grow faster than the Chinese market.
- Current share price is below our estimate of fair value.
- Dividends are not covered by earnings and cashflows.
- Annual earnings are forecast to grow slower than the Chinese market.
- See 002294's dividend history.
Next Steps:
Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Shenzhen Salubris Pharmaceuticals, there are three pertinent aspects you should further research:
- Risks: We feel that you should assess the 1 warning sign for Shenzhen Salubris Pharmaceuticals we've flagged before making an investment in the company.
- Future Earnings: How does 002294's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.